SG Americas Securities
DNLI icon

SG Americas Securities’s Denali Therapeutics DNLI Stock Holding History

SG Americas Securities’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Sell
42,339
-4,303
-9% -$88.4K ﹤0.01% 1821
2026
Q1 		$896K Sell
46,642
-102,950
-69% -$2.05M ﹤0.01% 1838
2025
Q4 		$2.47M Buy
149,592
+111,391
+292% +$1.88M ﹤0.01% 1403
2025
Q3 		$555K Buy
+38,201
New +$549K ﹤0.01% 2027
2025
Q2 		– Sell
-48,365
Closed -$658K – 3096
2025
Q1 		$658K Buy
48,365
+37,362
+340% +$716K ﹤0.01% 1549
2024
Q4 		$224K Buy
11,003
+6,195
+129% +$159K ﹤0.01% 2048
2024
Q3 		$140K Sell
4,808
-9,000
-65% -$223K ﹤0.01% 2793
2024
Q2 		$321K Buy
13,808
+6,667
+93% +$128K ﹤0.01% 1926
2024
Q1 		$147K Buy
+7,141
New +$134K ﹤0.01% 2224
2023
Q4 		– Sell
-35,800
Closed -$739K – 3181
2023
Q3 		$739K Buy
35,800
+26,326
+278% +$668K 0.01% 1503
2023
Q2 		$280K Sell
9,474
-27,817
-75% -$782K ﹤0.01% 1640
2023
Q1 		$859K Buy
37,291
+32,745
+720% +$901K 0.01% 1251
2022
Q4 		$126K Sell
4,546
-8,305
-65% -$247K ﹤0.01% 2556
2022
Q3 		$394K Sell
12,851
-26,465
-67% -$860K ﹤0.01% 1759
2022
Q2 		$1.16M Buy
39,316
+30,336
+338% +$795K 0.01% 1170
2022
Q1 		$289K Sell
8,980
-23,822
-73% -$820K ﹤0.01% 2217
2021
Q4 		$1.46M Buy
32,802
+1,907
+6% +$90.3K 0.01% 1350
2021
Q3 		$1.56M Buy
30,895
+13,625
+79% +$768K 0.01% 1510
2021
Q2 		$1.35M Sell
17,270
-9,908
-36% -$613K 0.01% 1360
2021
Q1 		$1.55M Buy
27,178
+1,559
+6% +$104K 0.01% 1221
2020
Q4 		$2.15M Sell
25,619
-57,528
-69% -$3.48M 0.01% 1055
2020
Q3 		$2.98M Buy
83,147
+62,766
+308% +$1.89M 0.02% 536
2020
Q2 		$493K Sell
20,381
-1,905
-9% -$44.8K ﹤0.01% 2106
2020
Q1 		$390K Buy
22,286
+7,086
+47% +$148K ﹤0.01% 2041
2019
Q4 		$265K Sell
15,200
-19,910
-57% -$331K ﹤0.01% 2277
2019
Q3 		$538K Buy
35,110
+25,668
+272% +$490K ﹤0.01% 1839
2019
Q2 		$196K Buy
9,442
+467
+5% +$10.5K ﹤0.01% 2419
2019
Q1 		$208K Buy
+8,975
New +$188K ﹤0.01% 2536

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG Americas Securities's DNLI Position: Q2 2026 in Review

SG Americas Securities reduced its Denali Therapeutics (DNLI) stake by 9.2% in Q2 2026, selling an estimated $88.4K and leaving 42,339 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1821.

SG Americas Securities first reported a position in DNLI in Q1 2019 and has held it in 28 quarters since. The position peaked at $2.98M in Q3 2020. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • SG Americas Securities held 42,339 shares of Denali Therapeutics worth $1.09M as of Q2 2026.
  • SG Americas Securities sold 4,303 Denali Therapeutics shares in Q2 2026, an estimated $88.4K.
  • Denali Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1821 holding.
  • SG Americas Securities first reported a position in Denali Therapeutics in Q1 2019 and has held it in 28 quarters since.
  • SG Americas Securities's Denali Therapeutics position peaked at $2.98M in Q3 2020.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.